Clinical evidence dossier
Vitamin D supplementation
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 5
- Supporting studies available for review
- 5
- Randomized trials
- 4
- Reported effects
- 2
Clinical conclusion
Vitamin D supplementation shows a moderate positive evidence signal for improving HbA1c across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
-6.8 to -6.8 %
Between-group effect
Mean difference
-0.82 to -0.82 % HbA1c
Evidence composition
- Non-randomized studies
- 1
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 2
Consistency
Authoritative consistency classification
mostly_consistent
- Positive
- 2
- No effect
- 3
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 5 of 5 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Individuals diagnosed with Type 1 Diabetes.
- Patients experiencing partial clinical remission.
- Those considering vitamin D supplementation for diabetes management.
- Adult males diagnosed with type 2 diabetes.
- Patients seeking to manage diabetes through supplementation.
- Women diagnosed with prediabetes.
- Individuals at risk for developing type 2 diabetes.
- Adults diagnosed with Type 2 Diabetes.
- Patients experiencing vascular complications related to diabetes.
- Adults newly diagnosed with type 2 diabetes
- Patients seeking additional therapies for glycemic control
Limitations
- 3 supporting studies do not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: baseline_within_group, placebo, usual_care.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.